The stock price of Akebia Therapeutics Inc (NASDAQ: AKBA) has jumped by 0.29 compared to previous close of 2.10. Despite this, the company has seen a fall of -2.95% in its stock price over the last five trading days. seekingalpha.com reported 2025-02-10 that Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia’s declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA’s signature HIF pathway. So far, it has shown some early successes, which makes me optimistic. AKBA is also working on a Phase 3 trial for non‑dialysis CKD patients, which is scheduled for mid‑2025 to support a potential label expansion.
Is It Worth Investing in Akebia Therapeutics Inc (NASDAQ: AKBA) Right Now?
The stock has a 36-month beta value of 0.92. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AKBA is 206.45M, and at present, short sellers hold a 7.00% of that float. On February 12, 2025, the average trading volume of AKBA was 2.17M shares.
AKBA’s Market Performance
AKBA stock saw an increase of -2.95% in the past week, with a monthly gain of 12.62% and a quarterly increase of 8.56%. The volatility ratio for the week is 2.62%, and the volatility levels for the last 30 days are 5.09% for Akebia Therapeutics Inc (AKBA). The simple moving average for the last 20 days is -4.13% for AKBA’s stock, with a simple moving average of 37.86% for the last 200 days.
Analysts’ Opinion of AKBA
Many brokerage firms have already submitted their reports for AKBA stocks, with BTIG Research repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to BTIG Research is $4 based on the research report published on November 29, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $3.75. The rating they have provided for AKBA stocks is “Buy” according to the report published on August 28th, 2023.
Piper Sandler gave a rating of “Overweight” to AKBA, setting the target price at $4 in the report published on May 31st of the previous year.
AKBA Trading at 4.10% from the 50-Day Moving Average
After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.08% of loss for the given period.
Volatility was left at 5.09%, however, over the last 30 days, the volatility rate increased by 2.62%, as shares surge +11.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.18% upper at present.
During the last 5 trading sessions, AKBA fell by -3.00%, which changed the moving average for the period of 200-days by +58.27% in comparison to the 20-day moving average, which settled at $2.20. In addition, Akebia Therapeutics Inc saw 10.84% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKBA starting from Butler John P., who sale 144,250 shares at the price of $2.10 back on Feb 03 ’25. After this action, Butler John P. now owns 2,604,330 shares of Akebia Therapeutics Inc, valued at $302,925 using the latest closing price.
Burke Steven Keith, the SVP, Chief Medical Officer of Akebia Therapeutics Inc, sale 50,506 shares at $2.10 during a trade that took place back on Feb 03 ’25, which means that Burke Steven Keith is holding 816,234 shares at $106,063 based on the most recent closing price.
Stock Fundamentals for AKBA
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.63 for the gross margin
The net margin for Akebia Therapeutics Inc stands at -0.27. The total capital return value is set at -0.25.
Based on Akebia Therapeutics Inc (AKBA), the company’s capital structure generated -26.68 points at debt to capital in total, while cash flow to debt ratio is standing at -0.79. The debt to equity ratio resting at -0.96. The interest coverage ratio of the stock is -2.73.
Currently, EBITDA for the company is -6.87 million with net debt to EBITDA at 2.79. When we switch over and look at the enterprise to sales, we see a ratio of 2.79. The receivables turnover for the company is 5.28for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
Conclusion
To sum up, Akebia Therapeutics Inc (AKBA) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
